西格列汀聯(lián)合預(yù)混胰島素治療脆性糖尿病伴高脂血癥療效

李燕

[摘要] 目的 分析西格列汀聯(lián)合預(yù)混胰島素治療脆性糖尿病伴高脂血癥的療效。方法 按照隨機抽樣的方式，從該院2018年3月—2019年3月的脆性糖尿病伴高脂血癥患者中，選取110例作為研究對象。對患者的臨床資料進(jìn)行整理，確定其完備性后，按照雙色球分組的方式將其劃分為兩組——對照組（n=55）和觀察組（n=55），前者采取單純的預(yù)混胰島素治療，后者采取西格列汀聯(lián)合預(yù)混胰島素治療。對兩組患者治療前、持續(xù)用藥12周以后的血糖指標(biāo)與血脂指標(biāo)進(jìn)行觀察。結(jié)果 兩組患者治療前的血糖指標(biāo)與血脂指標(biāo)比較，差異無統(tǒng)計學(xué)意義（P>0.05）;在治療后，觀察組患者與對照組患者的血糖指標(biāo)與血脂指標(biāo)相比較，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 西格列汀聯(lián)合預(yù)混胰島素治療脆性糖尿病伴高脂血癥的臨床效果較好，能夠?qū)颊叩难桥c血脂水平進(jìn)行調(diào)整，且安全性較高，值得推廣。

[關(guān)鍵詞] 西格列汀;預(yù)混胰島素;脆性糖尿病;高脂血癥;療效

[中圖分類號] R587? ? ? ? ? [文獻(xiàn)標(biāo)識碼] A? ? ? ? ? [文章編號] 1672-4062（2020）01（b）-0084-02

[Abstract] Objective To analyze the efficacy of sitagliptin combined with premixed insulin in the treatment of fragile diabetes with hyperlipidemia. Methods According to the random sampling method， 110 patients with brittle diabetes mellitus and hyperlipidemia from the hospital from March 2018 to March 2019? were selected as the research subjects. After the patient's clinical data were sorted out and their completeness was determined， they were divided into two groups according to the two-color ball grouping method： the control group （n=55） and the observation group （n=55）. The former adopted pure premixed insulin treatment， the latter was treated with sitagliptin in combination with premixed insulin. The blood glucose index and blood lipid index of the two groups of patients before and after 12 weeks of treatment were observed. Results There was no statistically significant difference in blood glucose index and blood lipid index between the two groups（P>0.05）. After treatment， the blood glucose index and blood lipid index of the observation group and the control group were statistically significant（P<0.05）. Conclusion Sitagliptin combined with premixed insulin is effective in the treatment of fragile diabetes with hyperlipidemia. It can adjust the blood glucose and blood lipid levels of patients， and it is safe and worth promoting.

[Key words] Sitagliptin; Premixed insulin; Fragile diabetes; Hyperlipidemia; Efficacy

隨著當(dāng)前社會環(huán)境的優(yōu)化，人們的飲食條件在逐漸提升，這就使得各種代謝性疾病的發(fā)生率逐年上升。糖尿病作為臨床相對常見的一種疾病，其多是因個體的胰島素分泌存在異常所致。脆性糖尿病作為一種不穩(wěn)定型糖尿病，在患病后患者會存在血糖波動較大、血糖難以控制、病情不穩(wěn)定性較強、容易誘發(fā)其他并發(fā)癥等臨床癥狀[1]。且由于脆性糖尿病的存在，患者的免疫系統(tǒng)會受損，其他疾病的誘發(fā)可能性相對提高，因此，多數(shù)脆性糖尿病患者都伴隨著其他疾病。高脂血癥作為常見的一種伴隨疾病，多表現(xiàn)為患者的體內(nèi)脂質(zhì)代謝紊亂，血脂水平異常[2]。這就……